Sanofi (NASDAQ:SNY) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,707,057 shares of the company's stock after purchasing an additional 29,536 shares during the quarter. American Century Companies Inc. owned 0.07% of Sanofi worth $82,331,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of SNY. Abel Hall LLC boosted its position in shares of Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after acquiring an additional 194 shares in the last quarter. Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after buying an additional 217 shares during the period. Bailard Inc. raised its stake in shares of Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after buying an additional 220 shares in the last quarter. Old Port Advisors grew its stake in shares of Sanofi by 0.6% during the 4th quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after purchasing an additional 232 shares during the period. Finally, ORG Partners LLC boosted its stake in shares of Sanofi by 17.7% during the 4th quarter. ORG Partners LLC now owns 1,681 shares of the company's stock worth $81,000 after acquiring an additional 253 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Remove Ads

Sanofi Stock Performance

Shares of NASDAQ SNY traded up $0.91 during trading on Friday, reaching $55.82. The stock had a trading volume of 2,059,619 shares, compared to its average volume of 2,268,963. The stock has a market cap of $141.66 billion, a PE ratio of 22.42, a P/E/G ratio of 1.01 and a beta of 0.58. The firm's 50 day moving average price is $55.03 and its two-hundred day moving average price is $52.85. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.